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HIV prevention
EC, PEP, PEPSE, HAART. The nursing profession is constantly being bombarded with
abbreviations and acronyms, but do you recognise these particular ones? How do they
relate to nursing care? And what are their implications for HIV prevention? David Evans
describes the process of PEPSE – postexposure prophylaxis following sexual exposure
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F rom a sexual health perspective, “EC” refers toemergency (hormonal) contraception, mistakenlycalled “the morning-after pill” as it can be taken up
to 72 hours after unprotected sexual intercourse (UPSI
– another abbreviation!). PEP is a form of EC; it stands
for postexposure prophylaxis, a protection, or prophy-
lactic, after a particular exposed event. HIV PEP has
“generally” been available to healthcare workers
(HCWs) in the UK after potential occupational exposure
to the virus, for example through needlestick injuries,
since publication of the guidelines by the Department of
Health in 2000.1 However, formal guidelines and proce-
dures are now widening access to HIV PEP following
certain genuinely risky sexual exposures (PEPSE) or
injecting drug use. This article explores the concept of
PEPSE and the urgent necessity for nurses, especially in
primary care, to be aware of its uses and availability.
The increasing role of PEP 
in primary HIV prevention 
Since the discovery of AIDS in 1981, and HIV in 1985,
scientific knowledge on the modes of transmission, spe-
cific types of retrovirus and antiretroviral (ARV) thera-
pies has progressed in leaps and bounds.2,3 Sadly, these
advances do not yet include an effective vaccine against
primary HIV infection – safer-sex messages, skills,
resources and practices are still essential. Neither is
there a vaccine to prevent the HIV infection progressing
to become an AIDS-defining illness. 
What has been developed, however, and what offers
unprecedented benefits in quality and quantity of life
for around three-quarters of people taking them, are a
group of medications referred to as “combination ther-
apy” or highly active antiretroviral therapy (HAART).
Regrettably, and controversially, these drugs are too
expensive for about 95% of HIV-infected people across
the world.
These drugs work by successfully interfering with
different points in the HIV lifecycle (see Figure 1 and
Table 1). There are about 21 drugs to date, most of
which have been developed since 1997; hence their
newness, cost, side-effects and the sometimes “experi-
mental” nature in finding the right combination for
different individuals.
PEPSE typically comprises a four-week course of
combination therapy, such as two NRTIs and one PI (or
boosted PI). (Exact details can be found at
www.bashh.org/guidelines) 
The Chief Medical Officer’s Independent Advisory
Group on AIDS issued guidelines to healthcare profes-
sionals, occupationally exposed to HIV, for using a
combination of these drugs at the time of potential infec-
tion.1 Even though there are thousands of occupational
accidents in the UK each year that might expose an indi-
vidual to bloodborne pathogens, the HIV infection rate
through this route has fortunately remained exception-
ally low. In the UK, out of over 66,000 people infected
with HIV, only five healthcare workers have been
assumed definitely to have been infected through
accidental exposure (source: www.hpa.org.uk). 
The guidelines explained first-aid measures for occu-
pational exposure, as well as the necessity to seek advice
about PEP immediately – if not within the first hour,
then as soon as possible after, up to a maximum of 72
hours after the incident. The guidelines also explained
that PEP would most certainly not be necessary on each
and every occupational exposure to potentially infected
contaminants. However, if started, it was imperative that
the full course be taken as prescribed – for four weeks.
The guidelines also suggested that certain physicians,
such as those who work in sexual health/genitourinary
services, might consider prescribing the PEP course in
exceptional circumstances for sexual (or injecting drug)
exposure, particularly in cases of rape by a HIV-positive
person. Government guidelines continue to emphasise
the imperative for all carers with clinical patient contact
to be vaccinated against hepatitis B.
Sex, drugs and HIV
prevention: a case for PEPSE
Did you know?
There were 38 million people estimated to be living with 
HIV in 2003, including 5 million new infections that year –
ie, 10 people infected every minute of the day! 
www.unaids.org
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HIV prevention
While the 2000 guidelines were a welcome move
forward on the part of carers who may be occupationally
exposed to HIV, given the relatively tiny chance of occu-
pational infection compared with the known predomi-
nant mode of infection – unprotected sexual intercourse,
particularly anal sex – it left the HIV policymakers open
to criticism: why were those most vulnerable to HIV
infection not being offered anything like the protection
measures available to those at significantly less risk?4,5
The reasons for not routinely providing PEPSE were
based around:
● The limited access to the medications.
● The fact that no clinical trials had been performed
to validate the use of PEP for UPSI.
● Fear of overprescribing or overuse of the drugs.
● A potential diminution of emphases on safer-sex
practices if individuals thought there was a
“morning-after pill” solution.
● The improbability of all these people actually
adhering to the strict medication regimen
(including numerous side-effects).
● And, of course, the cost!
Stigma
However, for some, the message sank deeper than all
of the reasons as to why PEP was not being provided
for sexual exposure (and after unsafe injecting drug
use). More than any other health condition in recent
centuries, HIV tapped into judgemental notions of
innocence and guilt, punishments and just rewards.6–8 
These new initiatives to provide PEP to people
significantly more at risk is therefore a welcome
development, not simply from an epidemiological
point of view, but also in reducing stigma and blame
around HIV.9 However, as Sowadsky reminds us,
“These drugs are not candy! They should not be
prescribed just to give a person peace of mind. They
should only be prescribed when treatment with these
drugs is clinically indicated. These are powerful drugs
and must be taken following strict dosing guidelines;
side-effects are very common, and can sometimes be
very serious.”10
In the UK, the largest section of the population most
vulnerable to new HIV infections continues to be gay,
bisexual and other men-who-have-sex-with-men (source
www.hpa.org.uk). The Terrence Higgins Trust’s
Community HIV and AIDS Prevention Service
(CHAPS) is a campaign to alert these men to the grow-
ing availability of PEP. The CHAPS programme has
developed awareness campaigns on PEPSE through
leaflets, posters, a website and a specially designed pack
for healthcare professionals. 
Potential impact on provision of care
The national guidelines on the prescribing of PEP for
SE are outlined by the British Association for Sexual
Health and HIV (BASHH)11 and cover wide-ranging
issues from the potential risk of exposure, the likeli-
hood of “donor” infectiousness, susceptibility of the
host, to the preferred medications to give and the
development of local services for increased access,
especially in areas of high local prevalence (see Table
2). As newer anti-HIV drugs are being developed, and
as prescribing regulations change in line with expert
opinion, evidence and research findings, this article
will not present drug regimens, but encourages you to
see the most recent and up-to-date guidelines offered
by BASHH (see Resources). 
Step 1
Virus enters bloodstream: eg, through unprotected
sexual intercourse with a HIV-infected person
Step 2
Virus searches out and latches onto cells with CD4
receptor sites (normal CD4+ count for adults around
800/µl blood) – especially the T4+, or “T-helper”
white blood cell
Step 3
Virus sheds its outer coat and inserts inner core, with
it genetic code (RNA), into the host cell
Step 4
Viral RNA leaves its core and, through the enzyme
reverse transcriptase, changes from RNA to DNA
and impregnates the host cell’s genetic code
Step 5
This “proviral DNA” triggers the cell to make massive
numbers of new copies of proviral DNA
Step 6
The new proviral DNA reverts back into viral RNA
Step 7
The new viral RNA begins the process of gathering
all the other materials it needs to form a fully
functioning virus (HIV) 
Step 8
The new viral particles bud out of the cell and
destroy it, thereby lowering the numbers of CD4 cells
Step 9
The virus seeks out other CD4 cells to infect 
For excellent diagrammatic images of this process, see
www.avert.org.uk, www.thebody.com and
www.aidsmeds.com
Figure 1
Basic lifecycle of HIV
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HIV prevention
Overcoming stigma and prejudice
One frequent accusation is that if PEP becomes more
widely available, individuals will stop practising safer
sex. According to limited studies so far, there is no
clear evidence to support this accusation.12,13 Safer-sex
messages, education, skills, resources such as con-
doms and counselling for those who need it are still by
far the most effective ways to prevent HIV transmis-
sion. Given the noticeable increase in new infections
in under-24-year-old gay and bisexual males, there is
evidence that such wide-ranging prevention is still
underdeveloped, ineffectively used and often erro-
neously undermined.14 PEP is just one other resource
in the fight against HIV infection.
Where to provide PEPSE
Rapid access to PEP and knowledge of its local avail-
ability, by healthcare professionals who can refer on
to it, is imperative in all areas where HIV transmis-
sion could be an issue, especially in higher preva-
lence areas such as major cities.15 The BASHH
Guidelines state how provision of PEP is needed on
a 24-hour basis and may involve certain areas of
service provision being “skilled up”, such as accident
and emergency departments, pharmacies, NHS
Direct, out-of-hour GP and walk-in services (again,
most particularly in areas of high incidence of HIV),
and services for people who have experienced aggra-
vated sex (anything from rough or traumatic sex
through to rape).11 PEP should also be available to
all services that deal with HIV-serodiscordant cou-
ples (where one partner is HIV-positive and the
other one is not), commercial sex workers and 
HIV-negative people who are unable to prevent
unprotected sex with a positive partner.
Issues, developments and clinical governance
Sections of the media routinely talk about “wasting
taxpayer’s money” and of people not “deserving” cer-
tain treatments. No truer is this than in the area of
sexual health, where many people’s gut reaction is
“you know the risk – the decision is yours!” A 28-day
course of PEP currently costs about £600, but in com-
parison with the possible costs of treating a person
with HIV (approximately £181,000),11 PEPSE is most
definitely a cost-effective programme.13,16 Many stud-
ies have also revealed that the availability of PEP does
not lead to a reduction in other primary prevention
Group name Pharmacological action
Fusion/entry inhibitors or uncoating inhibitors Prevent the virus latching onto cells or uncoating and 
hence releasing their inner core into the host cell
Nucleoside analogues (NAs)/nucleoside reverse Inhibit RNA-to-DNA reverse transcription. NAs/NRTIs 
transcription inhibitors (NRTIs or “nukes”) are faulty building blocks that mimic HIV’s enzyme 
“reverse transcriptase”, which is necessary for viral 
replication
Non-nucleoside reverse transcriptase inhibitors Have the same outcome as the “nukes”, but work by 
(NNRTIs or “non-nukes”) blocking the action of reverse transcriptase
Protease inhibitors (PIs) Prevent the protein building blocks of new viral particles 
getting together to leave the infected cell and bud out 
to infect others
Newer drugs Includes drugs that do not have the same basis as the 
other groups but still inhibit the viral lifecycle
Table 1. Classification of HAART medications and primary actions
Source is known to have HIV HIV status is unknown but 
from group or area with HIV 
prevalence greater than 10%
Receptive anal sex PEP recommended PEP recommended
Insertive anal sex PEP recommended PEP considered
Fellatio with ejaculation PEP considered PEP considered
Fellatio without ejaculation PEP not recommended PEP not recommended
Semen in eye (an example of PEP considered Not stated
mucous membrane exposure)
Table 2. Sexual exposure and PEP recommendations
HIV prevention
(safer-sex) practices by individuals, nor is there evi-
dence of individuals coming back time and again for
more PEP. Obviously, if this were the case, coun-
selling an individual about why they are frequently at
risk of HIV infection would be a preferred option.
Such counselling would highlight the fact that viral
strains are increasingly becoming resistant to many of
the medications used in PEP, and therefore they are
potentially risking failure.
Due to extending PEP guidelines to cover sexual
exposure, in line with local sexual health (PCT) leads
and budget-holders, primary care facilities will need to
audit their current approaches to people potentially
exposed to HIV through unprotected sex, to assess the
level of service they should be providing to their clients.
This may include:
● Enthusiastically promoting information on
PEPSE, especially targeting those most vulnerable
to HIV infection, using education, advertising and
clear signposting.
● Visibly highlighting how, where and when PEP
can be accessed.
● Deciding which services will hold short courses of
PEP (eg, 5-day “starter packs”, which can either
be discontinued or upgraded to 28 days when a
client is referred to the specialist service).
● Ensuring that trusts develop appropriate policies
of implementation, realising that just because no
clients have asked for PEPSE doesn’t mean that
there are no clients who need it.11,17
● Guaranteeing customised education for all staff
who will have a role in working with people
requiring PEPSE, including the ability to discuss
sexual matters in a nonjudgemental way, and the
ability to convey information on the rationale for
PEPSE, the lack of conclusive evidence of its
effectiveness, possible risks and side-effects, and
the necessity to receive continuing care from a
HIV/GU specialist service.11,18
Conclusion 
New developments in making anti-HIV PEP more wide-
ly available in cases of sexual exposure urgently require
more appropriately prepared and trained staff, greater
public and health service awareness of the initiatives, as
well as financial resources for particular services.
Once again, nurses and midwives are uniquely
placed in their therapeutic encounters with clients or
patients to deal with issues of sexual health. This new
development offers nurses an amazing role in multi-
professional initiatives aimed at increasing primary
prevention of HIV. ❖
HIV IN HEALTHCARE:
addressing stigma & discrimination
The National AIDS Trust’s
HIV in Healthcare
resource pack provides
guidance and practical
tools to address and avoid
HIV-related discrimination
in primary care.The pack
is specifically for
healthcare professionals
not working directly on
HIV (e.g. nurses, dentists,
GPs and other staff in
medical practices).
HIV in healthcare:
addressing stigma & discrimination
www.areyouhivprejudiced.org
Resource pack
The pack contains:
■ Informative and educational fact files 
■ Case studies of HIV-related stigma and
discrimination 
■ Information on disability legislation
■ Guidance on the fair treatment of 
HIV-positive patients
■ Practical tools on using the materials in
different situations 
■ Examples of NAT’s other relevant resources
■ Further sources of information and advice
To order a copy of the pack (£11+ £4 p&p)
visit http://shop.nat.org.uk or email
hivinhealthcare.nip@nat.org.uk
For more information on the pack and what 
NAT is doing to tackle HIV stigma and
discrimination, visit
www.areyouhivprejudiced.org/hivinhealthcare
By ending ignorance, we’ll end prejudice.
